NCT05548205View on ClinicalTrials.gov

Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge

NARecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions

Diabetes

Interventions

DEVICE

Continuous Glucose Monitor

Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.

DEVICE

Blood Glucose Monitor

Self-administered according to investigator instruction.

Trial Locations (1)

11501

RECRUITING

NYU Langone Hospital - Long Island, Mineola

All Listed Sponsors

lead

NYU Langone Health

OTHER